These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 32640076)

  • 1. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
    Linhart A; Germain DP; Olivotto I; Akhtar MM; Anastasakis A; Hughes D; Namdar M; Pieroni M; Hagège A; Cecchi F; Gimeno JR; Limongelli G; Elliott P
    Eur J Heart Fail; 2020 Jul; 22(7):1076-1096. PubMed ID: 32640076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.
    Linhart A; Paleček T
    Cardiovasc Diagn Ther; 2021 Apr; 11(2):650-660. PubMed ID: 33968642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.
    Hung CL; Wu YW; Lin CC; Lai CH; Jyh-Ming Juang J; Chao TH; Kuo L; Sung KT; Wang CY; Wang CL; Chu CY; Yu WC; Hou CJ
    Acta Cardiol Sin; 2021 Jul; 37(4):337-354. PubMed ID: 34257484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
    Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
    PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: A fundamental genetic modifier of cardiac function.
    Tadevosyan A
    Curr Res Transl Med; 2017; 65(1):10-14. PubMed ID: 28340691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry Disease and the Heart: A Comprehensive Review.
    Azevedo O; Cordeiro F; Gago MF; Miltenberger-Miltenyi G; Ferreira C; Sousa N; Cunha D
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine in Fabry disease.
    Lenders M; Brand E
    Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry Disease: The Current Treatment Landscape.
    Lenders M; Brand E
    Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic advances in Fabry disease: The future awaits.
    Kant S; Atta MG
    Biomed Pharmacother; 2020 Nov; 131():110779. PubMed ID: 33152937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
    Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Management of Cardiovascular Involvement in Fabry Disease.
    Rubino M; Monda E; Lioncino M; Caiazza M; Palmiero G; Dongiglio F; Fusco A; Cirillo A; Cesaro A; Capodicasa L; Mazzella M; Chiosi F; Orabona P; Bossone E; Calabrò P; Pisani A; Germain DP; Biagini E; Pieroni M; Limongelli G
    Heart Fail Clin; 2022 Jan; 18(1):39-49. PubMed ID: 34776082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Management of Fabry Disease in High-Risk Renal Disease Patients in Taiwan: A Single Center Study.
    Shih CY; You ZH; Tsai SF; Wu MJ; Yu TM; Chuang YW; Chen CH
    Transplant Proc; 2023 May; 55(4):788-791. PubMed ID: 37230899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.
    Besada P; Gallardo-Gómez M; Pérez-Márquez T; Patiño-Álvarez L; Pantano S; Silva-López C; Terán C; Arévalo-Gómez A; Ruz-Zafra A; Fernández-Martín J; Ortolano S
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of Molecular Mechanisms in Fabry Disease.
    Amodio F; Caiazza M; Monda E; Rubino M; Capodicasa L; Chiosi F; Simonelli V; Dongiglio F; Fimiani F; Pepe N; Chimenti C; Calabrò P; Limongelli G
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.